CNS adverse events associated with antiepileptic drugs

CNS Drugs

Volumn 22, Issue 9, 2008, Pages 739-760

  Kennedy, Gina M ^a   Lhatoo, Samden D ^a  

^a FRENCHAY HOSPITAL   (United Kingdom)

Author keywords

Antiepileptic drugs, adverse reactions; Benzodiazepines, adverse reactions; Carbamazepine, adverse reactions; Ethosuximide, adverse reactions; Felbamate, adverse reactions; Gabapentin, adverse reactions; Lamotrigine, adverse reactions

Indexed keywords

ACETYLSALICYLIC ACID; ANTICONVULSIVE AGENT; BARBITURIC ACID DERIVATIVE; BENZODIAZEPINE DERIVATIVE; CARBAMAZEPINE; CARBONATE DEHYDRATASE; CLOBAZAM; CLONAZEPAM; CORTICOSTEROID; ETHOSUXIMIDE; ETIRACETAM; FELBAMATE; GABAPENTIN; LAMOTRIGINE; OXCARBAZEPINE; PHENOBARBITAL; PHENYTOIN; PREGABALIN; PRIMIDONE; TIAGABINE; TOPIRAMATE; VALPROIC ACID; VIGABATRIN; WARFARIN; ZONISAMIDE;

ABDOMINAL PAIN; ACCIDENTAL INJURY; ADD ON THERAPY; AGGRESSION; AGITATION; ALLERGIC RASH; ALOPECIA; AMMONIA BLOOD LEVEL; AMNESIA; ANEMIA; ANOREXIA; ANXIETY; APLASTIC ANEMIA; APPETITE; ARTHRITIS; ASTHENIA; ASTHMA; ATAXIA; BACKACHE; BEHAVIOR CHANGE; BEHAVIOR DISORDER; BLEEDING; BRAIN DISEASE; CENTRAL NERVOUS SYSTEM DISEASE; CHEST INFECTION; COGNITION; COGNITIVE DEFECT; COMA; CONFUSION; CONSTIPATION; CONVULSION; COORDINATION DISORDER; DEPRESSION; DIABETES MELLITUS; DIARRHEA; DIPLOPIA; DISORIENTATION; DIZZINESS; DOSE RESPONSE; DROWSINESS; DRUG ACTIVITY; DRUG DOSE COMPARISON; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG FATALITY; DRUG METABOLISM; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSESTHESIA; DYSPEPSIA; DYSPNEA; ECZEMA; ENDOCRINE DISEASE; EPILEPSY; EPILEPTIC STATE; EYE DISEASE; FATIGUE; FLAPPING TREMOR; FLU LIKE SYNDROME; GASTROINTESTINAL DISEASE; GENERALIZED EPILEPSY; GENITAL SYSTEM DISEASE; HALLUCINATION; HEADACHE; HEARING IMPAIRMENT; HEART DISEASE; HEART INFARCTION; HEMATOLOGIC DISEASE; HEPATITIS; HEPATOBILIARY DISEASE; HUMAN; HYPERACTIVITY; HYPERAMMONEMIA; HYPERKINESIA; HYPERTENSION; IMPOTENCE; INFECTION; INJURY; INSOMNIA; INTELLIGENCE QUOTIENT; IRRITABILITY; ISCHEMIC HEART DISEASE; KIDNEY DISEASE; LENNOX GASTAUT SYNDROME; LETHARGY; LIBIDO DISORDER; LIVER DYSFUNCTION; LIVER FAILURE; LOW DRUG DOSE; LUNG DISEASE; MANIA; MEMORY DISORDER; MENTAL DISEASE; METABOLIC DISORDER; MONOTHERAPY; MOOD CHANGE; MOOD DISORDER; MOUTH DISEASE; MUSCULOSKELETAL DISEASE; MYALGIA; MYOCLONUS; MYOCLONUS SEIZURE; NAUSEA; NEOPLASM; NERVOUSNESS; NEUROLOGIC DISEASE; NYSTAGMUS; OCULOGYRIC CRISIS; OPHTHALMOPLEGIA; OROFACIAL DYSKINESIA; PAIN; PANCREATITIS; PARANOIA; PARESTHESIA; PARKINSONISM; PEPTIC ULCER; PERIPHERAL NEUROPATHY; PERSONALITY DISORDER; PHARYNGITIS; POLYDIPSIA; PRIORITY JOURNAL; PSORIASIS; PSYCHOSIS; RASH; RESPIRATORY TRACT DISEASE; RESTLESSNESS; REVIEW; RHINORRHEA; SEDATION; SEIZURE; SENSORY DYSFUNCTION; SIDE EFFECT; SINUSITIS; SKIN APPENDAGE DISEASE; SLEEP DISORDER; SOMNOLENCE; SPEECH DISORDER; STATISTICAL ANALYSIS; STROKE; STUPOR; SYNCOPE; TACHYCARDIA; THINKING IMPAIRMENT; THYROID DISEASE; TINNITUS; TRANSIENT ISCHEMIC ATTACK; TREMOR; UNSPECIFIED SIDE EFFECT; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION; URINE RETENTION; VAGINA BLEEDING; VASCULAR DISEASE; VEIN THROMBOSIS; VERTIGO; VISUAL DISORDER; VISUAL FIELD CONSTRICTION; VOMITING; WEIGHT GAIN; WEIGHT REDUCTION; WITHDRAWAL SEIZURE;

ANIMALS; ANTICONVULSANTS; CENTRAL NERVOUS SYSTEM DISEASES; EPILEPSY; HUMANS;

EID: 49549110688     PISSN: 11727047     EISSN: None     Source Type: Journal    
DOI: 10.2165/00023210-200822090-00003     Document Type: Review

References (203)

1. Ferner RE, Aronson JK. Communicating information about drug safety. BMJ 2006; 333: 143-5
2. Marson AG, Al-Kharusi AM, Alwaidh M, et al. The SANAD study of effectiveness of carbamazepine, gabapentin, lamotrigine, oxcarbazepine, or topiramate for treatment of partial epilepsy: an unblinded randomised controlled trial. Lancet 2007; 369: 1000-15
3. Marson AG, Al-Kharusi AM, Alwaidh M, et al. The SANAD study of effectiveness of valproate, lamotrigine, or topiramate for generalised and unclassifiable epilepsy: an unblinded randomised controlled trial. Lancet 2007; 369: 1016-26
4. Perucca E, Alexandre Jr V, Tomson T. Old versus new antiepileptic drugs: the SANAD study [letter]. Lancet 2007; 370: 313
5. Twyman RE, Rogers CJ, Macdonald RL. Differential regulation of gamma-aminobutyric acid receptor channels by diazepam and phenobarbital. Ann Neurol 1989; 25: 213-20
6. Koeppen D. A review of clobazam studies in epilepsy. In: Hindmarch I, Stonier PD, Trimble MR, editors. Clobazam, human psychopharmacology and clinical applications. London: Royal Society of Medicine; 1985: 1207-15
7. Cull CA, Trimble MR. Anticonvulsant benzodiazepines and performance. In: Hindmarch I, Stonier PD, Trimble MR, editors. Clobazam, human psychopharmacology and clinical applications. London: The Royal Society of Medicine, 1985: 121-8
8. Bawden HN, Camfield CS, Camfield PR, et al. The cognitive and behavioural effects of clobazam and standard monotherapy are comparable. Canadian Study Group for Childhood Epilepsy. Epilepsy Res 1999; 33 (2-3): 133-43
9. Naito H, Wachi M, Nishida M. Clinical effects and plasma concentrations of long-term clonazepam monotherapy in previously untreated epileptics. Acta Neurologica Scandinavica 1987; 76: 58-63
10. Rothschild AJ, Shindul-Rothschild, Vinguera A, et al. Comparison of the frequency of behavioural disinhibition on alprazolam, clonazepam, or no benzodiazepine in hospitalized psychiatric patients. J Clin Psychopharmacol 2000; 20: 7-11
11. Sato S, Penry JK, Dreifuss FE, et al. Clonazepam in the treatment of absence seizures. Neurology (Minneap) 1977; 27: 371
12. Colasanti BK, Craig CR. Reduction of seizure frequency by clonazepam during cobalt experimental epilepsy. Brain Res Bull 1992; 28: 329-31
13. Specht U, Boenigk HE, Wolf P. Discontinuation of clonazepam after long-term treatment. Epilepsia 1989; 30: 458-63
14. Wong T, Tiessen E. Seizure in gradual clonazepam withdrawal. Psychiatr J Univ Ottawa 1989; 14: 484
15. Bittencourt PRM, Richens A. Anticonvulsant-induced status epilepticus in Lennox-Gastaut syndrome. Epilepsia 1981; 22: 129-34
16. Bladin PF. The use of clonazepam as an anticonvulsant-clinical evaluation. Med J Aust 1973; 1: 683-8
17. Munthe-Kaas AW, Strandjord RE. Clonazepam in the treatment of epileptic seizures. Acta Neurol Scand 1973; 49: 97-102
18. Rosebuch PI, Mazurek MF. Catatonia after benzodiazepine withdrawal. J Clin Psychopharmacol 1996; 16: 315-9
19. Schwartz JR, Grigat G. Phenytoin and carbamazepine: potential and frequency-dependent block of Na currents in mammalian myelinated nerve fibres. Epilepsia 1989; 30: 286-94
20. Collaborative Group for Epidemiology of Epilepsy. Adverse reactions to antiepileptic drugs: a follow-up study of 355 patients with chronic antiepileptic drug treatment. Epilepsia 1988; 29: 787-93
21. Smith DB, Mattson RH, Cramer J, et al. Results of a nationwide Veterans Administration Cooperative Study comparing the efficacy and toxicity of carbamazepine, phenobarbitone, phenytoin and primidone. Epilepsia 1987; 28 Suppl. 3: S50-8
22. Chadwick DW, Shaw MDM, Foy P, et al. Serum anticonvulsant concentrations and the risk of drug-induced skin eruptions. J Neurol Neurosurg Psychiatry 1984; 47: 642-4
23. Brent DA, Crumrine PK, Varma RR, et al. Phenobarbital treatment and major depressive disorder in children with epilepsy. Pediatrics 1987; 80: 909-17
24. Pellock JM. Carbamazepine side effects in children and adults. Epilepsia 1987; 28 Suppl. 3: S64-70
25. Schmitz B, Trimble MR. PIP-syndrome in temporal lobe epilepsy. Epilepsy Res 1995; 22: 215-20
26. Dalby MA. Behavioural effects of carbamazepine. In: Penry JK, Daly DD, editors. Complex partial seizures and their treatment. Advances in neurology. Vol. 11. New York: Raven Press, 1975: 331-43
27. Drake ME, Peruzzi WT. Manic state with carbamazepine therapy of seizures. J Natl Med Assoc 1986; 78: 1105-10
28. Gorman M, Barkley GL. Oculogyric crisis induced by carbamazepine. Epilepsia 1995; 36 (11): 1158-60
29. Jacome D. Carbamazepine-induced dystonia [letter]. JAMA 1979; 241 (21): 2263
30. Thomas P, Valton L, Genton P. Absence and myoclonic status epilepticus precipitated by antiepileptic drugs in idiopathic generalized epilepsy. Brain 2006; 129 (5): 1281-92
31. Perucca E, Gram L, Avanzini G, et al. Antiepileptic drugs as a cause of worsening seizures. Epilepsia 1998; 39 (1): 5-17
32. Snead OC, Hosey LC. Exacerbation of seizures in children by carbamazepine. New Engl J Med 1985; 313: 916-21
33. Coulter DA, Huguenard JR, Prince DA. Characterization of ethosuximide reduction of low-threshold calcium current in thalamic neurons. Ann Neurol 1989; 25: 582-93
34. Browne T. Ethosuximide (Zarontin) and other succinimides. In: Browne T, Feldman R, editors. Epilepsy, diagnosis and management. Boston (MA): Little, Brown, 1983: 215-24
35. Sato S, White BG, Penry JK, et al. Valproic acid versus ethosuximide in the treatment of absence seizures. Neurology 1982; 32 (2): 157-63
36. Martinovic Z. Comparison of ethosuximide with sodium valproate as monotherapies of absence seizures. In: Parsonage M, Grant R, Craig A, et al., editors. Advances in epileptology: XIVth Epilepsy International Symposium. New York: Raven Press, 1983: 301-5
37. Callaghan N, O'Hare J, O'Driscoll D, et al. Comparative study of ethosuximide and sodium valproate in the treatment of typical absence seizures (petit mal). Dev Med Child Neurol 1982; 24 (6): 830-6
38. Schmitz B. Psychiatric syndromes related to antiepileptic drugs. Epilepsia 1999; 40 Suppl. 10: S65-70
39. Dreifuss F. Ethosuximide: toxicity. In: Levy RH, Mattson RH, Meldrum BS, editors. Antiepileptic drugs. New York: Raven Press, 1995: 675-9
40. Todorov A, Lenn N, Gabor A. Exacerbation of generalized non-convulsive seizures with ethosuximide therapy. Arch Neurol 1978; 35: 389-91
41. Snead OC. Seizure aggrevation: clinical assessment and role of AEDs. Antiepileptic Therapy Symposium, 2005; Washington, DC
42. Goldensohn E, Hardie J, Borea E. Ethosuximide in the treatment of epilepsy. JAMA 1962; 180: 840-2
43. Wang WZ, Wu JZ, Ma GY, et al. Efficacy assessment of phenobarbital in epilepsy: a large community-based intervention trial in rural China. Lancet Neurol 2006; 5 (1): 46-52
44. Nimaga K, Desplats D, Duoumbo O, et al. Treatment with phenobarbital and monitoring of epileptic patients in rural Mali. Bull World Health Organ 2002; 80 (7): 532-7
45. Pal DK, Das T, Chaudhury G, et al. Randomised controlled trial to assess acceptability of phenobarbital for childhood epilepsy in rural India. Lancet 1998; 351 (9095): 19-23
46. Theodore WH. Rational use of antiepileptic drug levels. Pharmacol Ther 1992; 54: 297-305
47. Pritchard JW, Mattson RA. Barbiturates: an update. In: Pedley TA, Meldrum BS, editors. Recent advances in epilepsy. Edinburgh: Churchill Livingstone, 1986: 261-77
48. Vining EP, Mellitis ED, Dorsen MM, et al. Psychological and behavioural effects of antiepileptic drugs in children: a double-blind comparison between phenobarbital and valproic acid. Pediatrics 1987; 80: 165-74
49. Cramer J, Mattson RH. Phenobarbital: toxicity. In: Levy RH, Mattson RH, Meldrum BS, editors. Antiepileptic drugs. 4th ed. New York: Raven Press, 1995: 409-20
50. Farwell JR, Lee YJ, Hirtz DG, et al. Phenobarbital for febrile seizures: effects on intelligence and on seizure recurrence [published erratum appears in N Engl J Med 1992 Jan 9; 326 (2): 144]. New Engl J Med 1990; 322 (6): 364-9
51. Reinisch JM, Sanders SA, Mortensen EL, et al. In utero exposure to phenobarbital and intelligence deficits in adult men. JAMA 1995; 274: 1518-25
52. Heller AJ, Chesterman P, Elwes RD, et al. Phenobarbitone, phenytoin, carbamazepine, or sodium valproate for newly diagnosed adult epilepsy: a randomised comparative monotherapy trial. J Neurol Neurosurg Psychiatry 1995; 58 (1): 44-50
53. Taylor S, Tudor SC, Williamson PR, et al. Phenobarbitone versus phenytoin monotherapy for partial-onset seizures and generalized onset tonic-clonic seizures. Cochrane Database Syst Rev 2001; (4): CD002217
54. Mattson RH, Cramer J, Collins JF, et al. Comparison of carbamazepine, phenobarbital, phenytoin, and primidone in partial and secondarily generalised tonic-clonic seizures. New Engl J Med 1985; 313: 145-51
55. Kwan P, Brodie MJ. Phenobarbital for the treatment of epilepsy in the 21st century: a critical review. Epilepsia 2004; 45 (9): 1141-9
56. Meador KJ, Loring DW, Huh K, et al. Comparative cognitive effects of anticonvulsants. Neurology 1990; 40: 391-4
57. Vandam LD, Collins WL. Recovery from acute phenobarbital intoxication after prolonged coma. JAMA 1963 Apr 20; 184: 239-41
58. Guerrini R, Belmonte A, Strumia S, et al. Exacerbation of epileptic negative myoclonus by carbamazepine or phenobarbital in children with atypical benign rolandic epilepsy. Epilepsia 1995; 36 Suppl. 3: S65
59. Wilder BJ, Rangel RJ. Clinically relevant antiepileptic drug interactions. In: WH Pitlick, editor. Antiepileptic drug interactions. New York: Demos Publications, 1989: 65-75
60. Kutt H, Winters W, Kokenge R, et al. Diphenylhydantoin metabolism, blood levels and toxicity. Arch Neurol 1964; 11: 642-8
61. Chua HC, Venketasubramanian N, Tan CB, et al. Paradoxical seizures in phenytoin toxicity. Singapore Med 1999; 40: 276-7
62. McLellan DL, Swash M. Choreo-athetosis and encephalopathy induced by phenytoin. BMJ 1974; 2: 204-5
63. Shorvon SD, Reynolds EH. Anticonvulsant peripheral neuropathy: a clinical and electrophysiological study of patients on single drug treatment with phenytoin, carbamazepine or barbiturates. J Neurol Neurosurg Psychiatry 1982; 47: 621-6
64. Bayer AU, Thiel HJ, Zrenner E, et al. Color vision tests for early detection of antiepileptic drug toxicity. Neurology 1997; 48: 1394-7
65. Trimble MR. Anticonvulsant drugs and cognitive function: a review of the literature. Epilepsia 1987; 28 Suppl. 3: S37-45
66. Aldenkamp AP, Alpherts WC, Diepman L, et al. Cognitive side effects of phenytoin compared with carbamazepine in patients with localization-related epilepsy. Epilepsy Res 1994; 19: 37-43
67. Kalviainen R, Aikia M, Riekkinen P. Cognitive adverse effects of antiepileptic drugs: incidence, mechanisms and therapeutic implications. CNS Drugs 1996; 5: 358-68
68. Tudur SC, Marson AG, Williamson PR. Phenytoin versus valproate monotherapy for partial-onset seizures and generalized onset tonic-clonic seizures. Cochrane Database Syst Rev 2001; (4): CD001769
69. Tudur SC, Marson AG, Clough HE, et al. Carbamazepine versus phenytoin monotherapy for epilepsy. Cochrane Database Syst Rev 2002; (2): CD001911
70. Ney GC, Lantos G, Barr WB, et al. Cerebellar atrophy in patients with long-term phenytoin exposure. Arch Neurol 1994; 51 (8): 767-71
71. Leppick I, Cloyd JC. Primidone: toxicity. In: Levy RH, Mattson RH, Meldrum BS, editors. Antiepileptic drugs. 4th ed. New York: Raven Press, 1995: 487-90
72. Randomised study of antiepileptic drug withdrawal in patients in remission. Medical Research Council Antiepileptic Drug Withdrawal Study Group. Lancet 1991; 337 (8751): 1175-80
73. McLean MJ, Macdonald RL. Sodium valproate, but not ethosuximide, produces use- and voltage-dependent limitation of high frequency repetitive firing of action potentials of mouse central neurons in cell culture. J Pharmacol Exp Ther 1986; 237: 1001-11
74. Kelly KM, Gross RA, Macdonald RL. Valproic acid selectivity reduces the low-threshold calcium current in rat nodose neurons. Neurosci Lett 1990; 116: 233-8
75. Goulden KJ, Dooley JM, Camfield PR, et al. Clinical valproate toxicity induced by acetylsalicylic acid. Neurology 1987; 37: 1392-4
76. Trimble MR, Thompson PJ. Sodium valproate and cognitive function. Epilepsia 1984; 25: S60-4
77. Meador KJ, Loring DW, Hulihan JF, et al. Differential cognitive and behavioural effects of topiramate and valproate. Neurology 2003; 60 (9): 1483-8
78. Keranen T, Sivenius J. Side effects of carbamazepine, valproate and clonazepam during long-term treatment of epilepsy. Acta Neurol Scand Suppl 1983; 97: 69-80
79. Masmoudi K, Gras-Champel V, Mason H, et al. Parkinsonism and/or cognitive impairment with valproic acid therapy: a report of ten cases. Pharmacopsychiatry 2006; 39 (1): 9-12
80. Murphy JV, Marquardt K. Asymptomatic hyperammonemia in patients receiving valproic acid. Arch Neurol 1982; 39: 591-3
81. Vossler DG, Wilensky AJ, Cawthorn DF, et al. Serum and CSF glutamine levels in valproate-related hyperammonemic encephalopathy. Epilepsia 2002; 43: 154-9
82. Verrotti A, Trotta D, Morgese G, et al. Valproate-induced hyperammonemic encephalopathy. Metab Brain Dis 2002; 17: 367-73
83. Triggs WJ, Bohan TP, Lin S, et al. Valproate-induced coma with ketosis and carnitine insufficiency. Arch Neurol 1990; 47: 1131-3
84. Rottach KG, Weiss-Brummer J, Wieland U, et al. Valproic acid in prophylaxis of bipolar disorder: a case of valproate-induced encephalopathy. Nervenarzt 2000; 71: 401-3
85. Reif A, Leonhard C, Mossner R, et al. Encephalopathy and myoclonus triggered by valproic acid. Prog Neuropsychopharmacology Biol Psychiatry 2004; 28: 1061-3
86. Vinten J, Adab N, Kini U, et al. Neuropsychological effects of exposure to anticonvulsant medication in utero. Neurology 2005; 64 (6): 949-54
87. Motamedi GK, Meador KJ. Antiepileptic drugs and neurodevelopment. Curr Neurol Neurosci Rep 2006; 6 (4): 341-6
88. Lhatoo SD, Wong IC, Polizzi G, et al. Long-term retention rates of lamotrigine, gabapentin, and topiramate in chronic epilepsy. Epilepsia 2000; 41 (12): 1592-6
89. Depondt C, Yuen AW, Bell GS, et al. The long term retention of levetiracetam in a large cohort of patients with epilepsy. J Neurol Neurosurg Psychiatry 2006; 77 (1): 101-3
90. Pellock JM, Watermberg N. New antiepileptic drugs in children: present and future. Semin Pediatr Neurol 1997; 4: 9-18
91. Pisani A, Spadoni F, Bernadi G. Electrophysiological actions of felbamate on rat striatal neurones. Br J Pharmacol 1995; 116: 2053-61
92. McCabe RT, Wasterlain CG, Kucharezyk N, et al. Evidence for anticonvulsant and neuroprotectant action of felbamate mediated by strychnine-insensitive glycine receptors. J Pharmacol Exp Ther 1993; 26: 1248-52
93. Leppick I. Felbamate. Epilepsia 1995; 36 Suppl. 2: S66-72
94. Bourgeois B. Felbamate. Semin Pediatr Neurol 1997; 4: 3-8
95. O'Neil MG, Perdun CS, Wilson MB, et al. Felbamate-associated fatal acute hepatic necrosis. Neurology 1996; 46: 1457-9
96. Wamil AW, McLean MJ. Limitation by gabapentin of high frequency action potential firing by mouse central neurons in cell culture. Epilepsy Res 1994; 17 (1): 1-11
97. Gotz E, Feuerstein TJ, Lais A, et al. Effects of gabapentin on release of gamma-amminobutyric acid from slices of rat neostriatum. Arzneimittelforschung 1993; 43 (6): 636-8
98. Gee NS, Brown JP, Dissanayake VU, et al. The novel anticonvulsant drug, gabapentin (Neurontin), binds to the alpha2delta subunit of a calcium channel. J Biol Chem 1996; 271 (10): 5768-76
99. Hill DR, Suman-Chauhan N, Woodruff GN. Localization of [3H]gabapentin to a novel site in rat brain: autoradiographic studies. Eur J Pharmacology 1993; 244 (3): 303-9
100. Cramer J, Fisher R, Ben-Menachem E, et al. New antiepileptic drugs: a comparison of key clinical trials. Epilepsia 1999; 40: 590-600
101. Devinsky O, Cramer J. Safety and efficacy of standard and new antiepileptic drugs. Neurology 2000; 55 Suppl. 3: 5-10
102. Marson AG, Kadir ZA, Hutton JL, et al. The new antiepileptic drugs: a systematic review of their efficacy and tolerability. Epilepsia 1997; 38 (8): 859-80
103. Gabapentin as add-on therapy in refractory partial epilepsy: a double-blind, placebo-controlled, parallel-group study. The US Gabapentin Study Group. Neurology 1993; 43 (11): 2292-8
104. Gabapentin in partial epilepsy. UK Gabapentin Study Group. Lancet 1990; 335 (8698): 1114-7
105. Anhut H, Ashman P, Feuerstein TJ, et al. Gabapentin (Neurontin) as add-on therapy in patients with partial seizures: a double-blind, placebo-controlled study. The International Gabapentin Study Group. Epilepsia 1994; 35 (4): 795-801
106. Sivenius J, Kalviainen R, Ylinen A, et al. Double-blind study of gabapentin in the treatment of partial seizures. Epilepsia 1991; 32 (4): 539-42
107. Litzinger MJ, Wiscombe N, Hanny A, et al. Increased seizures and aggression seen in persons with mental retardation and epilepsy treated with Neurontin [abstract]. Epilepsia 1995; 36 Suppl. 4: 71
108. Doherty KP, Gates JR, Penovich PE, et al. Gabapentin in a medically refractory epilepsy population: seizure response and unusual side effects [abstract]. Epilepsia 1995; 36 Suppl. 4: 71
109. Asconape J, Diedrich A, DellaBadia J. Myoclonus associated with the use of gabapentin. Epilepsia 2000; 41: 479-81
110. Leach JP, Marden CM, Miller AA. Pharmacological studies on lamotrigine, a novel potential antiepileptic drug: II. Neurochemical studies on the mechanism of action. Epilepsia 1986; 27: 490-7
111. Cheung H, Kamp D, Harris E. An in vitro investigation of the action of lamotrigine on neuronal voltage-activated sodium channels. Epilepsy Res 1992; 13: 107-12
112. Morrow J, Russell A, Guthrie L, et al. Malformation risks of antiepileptic drugs in pregnancy: a prospective study from the UK Epilepsy and Pregnancy Register. J Neurol Neurosurg Psychiatry 2006; 77: 193-8
113. Biton V, Sackellares JC, Vuong A, et al. Double-blind, placebo-controlled study of lamotrigine in primary generalized tonic-clonic seizures. Neurology 2005; 65 (11): 1737-43
114. Gamble C, Williamson PR, Chadwick DW, et al. A meta-analysis of individual patient responses to lamotrigine or carbamazepine therapy. Neurology 2006; 66 (9): 1310-7
115. Gamble C, Williamson PR, Marson AG. Lamotrigine versus carbamazepine monotherapy for epilepsy. Cochrane Database Syst Rev 2006; (1): CD001031
116. Matsuo F, Bergen D, Faught E, et al. Placebo-controlled study of the efficacy and safety of lamotrigine in patients with partial seizures. US Lamotrigine Protocol 0.5 Clinical Trial Group. Neurology 1993; 43 (11): 2284-91
117. Binnie CD, Debets RM, Engelsman M, et al. Double-blind crossover trial of lamotrigine (Lamictal) as add-on therapy in intractable epilepsy. Epilepsy Res 1989; 4 (3): 222-9
118. Jawad S, Richens A, Goodwin G, et al. Controlled trial of lamotrigine (Lamictal) for refractory partial seizures. Epilepsia 1989; 30 (3): 356-63
119. Loiseau P, Yuen AW, Duche B, et al. A randomized double-blind placebo controlled crossover add-on trial of lamotrigine in patients with treatment resistant partial seizures. Epilepsy Res 1990; 7 (2): 136-45
120. Messenheimer J, Ramsay RE, Willmore LJ, et al. Lamotrigine therapy for partial seizures: a multicenter, placebo-controlled, double-blind, crossover trial. Epilepsia 1994; 35 (1): 113-21
121. Schapel GJ, Beran RG, Vajda FJ, et al. Double blind, placebo-controlled, crossover study of lamotrigine in treatment-resistant partial seizures. J Neurol Neurosurg Psychiatry 1993; 56 (5): 448-53
122. Smith D, Baker G, Davies G, et al. Outcomes of add on treatment with lamotrigine in partial epilepsy. Epilepsia 1993; 34 (2): 312-22
123. Committee on Safety of Medicines and the MHRA (medicines). Reminder: lamotrigine (Lamictal) and serious skin reactions. Curr Probl Pharmacovigilance 1996; 22: 12
124. Messenheimer J, Mullens EL, Giorgi L, et al. Safety review of adult clinical trial experience with lamotrigine. Drug Saf 1998; 18 (4): 281-96
125. Beran RG, Gibson RJ. Aggressive behaviour in intellectually challenged patients with epilepsy treated with lamotrigine. Epilepsia 1998; 39 (3): 280-2
126. Wong IC, Lhatoo SD. Adverse reactions to new anticonvulsant drugs. Drug Saf 2000; 23 (1): 35-56
127. Aldenkamp AP, Arends J, Bootsman PR, et al. Randomized double-blind parallel-group study comparing cognitive effects of a low-dose lamotrigine with valproate and placebo in healthy volunteers. Epilepsia 2002; 43 (1): 19-26
128. Smith D, Baker G, Davies G, et al. Outcomes of add-on treatment with lamotrigine in partial epilepsy. Epilepsia 1993; 34: 312-22
129. Guerrini R, Dravet C, Genton P, et al. Lamotrigine and seizure aggravation in severe myoclonic epilepsy. Epilepsia 1998; 39 (5): 508-12
130. Biraben A, Allain H, Scarabin JM, et al. Exacerbation of juvenile myoclonic epilepsy with lamotrigine. Neurology 2000; 55 (11): 1757-8
131. Lynch AA, Lamberg N, Nocka K, et al. The synaptic vesicle protein SV2A is the binding site for the antiepileptic drug levetiracetam. Proc Natl Acad Sci 2004; 101 (26): 9861-6
132. Shorvon SD, Lowenthal A, Janz D, et al. Multicenter double-blind, randomised, placebo-controlled trial of levetiracetam as add-on therapy in patients with refractory partial seizures. Epilepsia 2000; 41 (9): 1179-86
133. Ramael S, Daoust A, Otoul C, et al. Levetiracetam intravenous infusion: a randomised, placebo-controlled safety and pharmacokinetic study. Epilepsia 2006; 47 (7): 1128-35
134. Mula M, Trimble MR, Yuen AW, et al. Psychiatric adverse events during levetiracetam therapy. Neurology 2003; 61 (5): 704-6
135. Brodtkorb E, Klees TM, Nakken KO, et al. Levetiracetam in adult patients with and without learning disability: focus on behavioural adverse effects. Epilepsy Behav 2004; 5 (2): 231-5
136. Mula M, Trimble MR, Sander JW. Psychiatric adverse events in patients with epilepsy and learning disabilities taking levetiracetam. Seizure 2004; 13 (1): 55-7
137. Kossoff EH, Bergey GK, Freeman JM, et al. Levetiracetam psychosis in children with epilepsy. Epilepsia 2001; 42 (12): 1611-3
138. Glauser TA, Pellock JM, Bebin EM, et al. Efficacy and safety of levetiracetam in children with partial seizures: an open label trial. Epilepsia 2002; 43 (5): 518-24
139. Houtkooper MA, Lammertsma A, Meyer JWA. et al. Oxcarbazepine (GP 47.680): a possible alternative to carbamazepine. Epilepsia 1987; 28: 693-8
140. Dam M, Ekberg R, Løyning Y, et al. A double-blind study comparing oxcarbazepine and carbamazepine in patients with newly diagnosed, previously untreated epilepsy. Epilepsy Res 1989; 3: 70-6
141. Van Amelsvoort T, Bakshi R, Devaux CB, et al. Hyponatremia associated with carbamazepine and oxcarbazepine therapy: a review. Epilepsia 1994; 35: 181-8
142. Schmidt D, Elger CE. What is the evidence that oxcarbazepine and carbamazepine are distinctly different antiepileptic drugs? Epilepsy Behaviour 2004; 5 (5): 627-35
143. Gram L. Oxcarbazepine. In: Engel S, Pedley T, editors. Epilepsy: a comprehensive textbook. Philadelphia (PA): Lippincott-Raven, 1997: 1541-6
144. Muller M, Marson AG, Williamson PR. Oxcarbazepine versus phenytoin monotherapy for epilepsy (review). Cochrane Database Syst Rev 2006; (3): CD003615
145. Gelisse P, Genton P, Kuate C, et al. Worsening of seizures by oxcarbazepine in juvenile idiopathic generalized epilepsies. Epilepsia 2004; 45: 282-6
146. Taylor CP, Vartanian MG. Profile of anticonvulsant activity of CI-1008 (pregabalin) in animal models. Epilepsia 1997; 38 Suppl. 8: 8
147. Arroyo S, Anhut H, Kugler AR, et al. Pregabalin add-on treatment: a randomised, double-blind, placebo-controlled, dose-response study in adults with partial seizures. Epilepsia 2004; 45 (1): 20-7
148. Elger CE, Brodie MJ, Anhut H, et al. Pregabalin add-on treatment in patients with partial seizures: a novel evaluation of flexible-dose and fixed-dose treatment in a double-blind, placebo-controlled study. Epilepsia 2005; 46 (12): 1926-36
149. White SH. Clinical significance of animal seizure models and mechanism of action studies of potential antiepileptic drugs. Epilepsia 1997; 38 (1): S9-17
150. Meldrum BS. Update on the mechanism of action of new antiepileptic drugs. Epilepsia 1996; 37 (6): S4-11
151. Macdonald RL, Greenfield LJ. Mechanisms of action of new antiepileptic drugs. Curr Opin Neurol 1997; 10: 121-8
152. Crawford P, Meinardi H, Brown S, et al. Tiagabine: efficacy and safety in adjunctive treatment of partial seizures. Epilepsia 2001; 42 (4): 531-8
153. Schachter SC. Tiagabine. Epilepsia 1999; 40 Suppl. 5: S17-22
154. Knake S, Hammer HM, Schomburg U, et al. Tiagabine-induced absence status in idiopathic generalised epilepsy. Seizure 1999; 8 (5): 314-7
155. Koepp MJ, Edwards M, Collins JF, et al. Status epilepticus and tiagabine therapy revisited. Epilepsia 2005; 46 (10): 1625-32
156. Fulton JA, Hoffman RS, Nelson LSN. Tiagabine overdose: a case of status epilepticus in a non-epileptic patient. Clin Toxicol 2005; 43 (7): 869-71
157. Wolanczyk T, Grabowska-Grzyb A. Transient dystonias in three patients treated with tiagabine. Epilepsia 2001; 42 (7): 944-6
158. Sorri I, Kalviainen R, Mantyjarvi M. Color vision and contrast sensitivity in epilepsy patients treated with initial tiagabine monotherapy. Epilepsy Res 2005; 67 (3): 101-7
159. White HS, Brown SD, Woodhead JH, et al. Topiramate enhances GABA-mediated chloride flux and GABA-evoked chloride currents in murine brain neurons and increases seizure threshold. Epilepsy Res 1997; 23: 167-79
160. Glauser TA. Topiramate. Epilepsia 1999; 40 Suppl. 5: 71-80
161. Privitera MD. Topiramate: a new antiepileptic drug. Ann Pharmacother 1997; 31: 1164-73
162. Reife RA, Lim P, Pledger G. Topiramate: side effect profile in double-blind studies. Epilepsia 1995; 36 Suppl. 4: 34
163. Lee S, Sziklas V, Andermann F, et al. The effects of adjunctive topiramate on cognitive function in patients with epilepsy. Epilepsia 2003; 44 (3): 339-47
164. Lee HW, Jung DK, Suh CK, et al. Cognitive effects of low-dose topiramate monotherpay in epilepsy patients: a one-year follow up. Epilepsy Behav 2006; 8 (4): 736-41
165. Sander JWAS. Practical aspects of the use of topiramate in patients with epilepsy. Epilepsia 1997; 38 Suppl. 1: S56-8
166. Gogol LM, Morris HH. The office use of topiramate:a review of seizure control and side effect profile [abstract]. Epilepsia 1998; 39 Suppl. 6: 55
167. Meador KJ, Loring DW, Vahle VJ, et al. Cognitive and behavioural effects of lamotrigine and topiramate in healthy volunteers. Neurology 2005; 64: 2108-14
168. Majkowski J, Neto W, Wapenaar R, et al. Time course of adverse events in patients with localisation-related epilepsy receiving topiramate added to carbamazepine. Epilepsia 2005; 46 (5): 648-53
169. Traub SJ, Howland MA, Hoffman RS, et al. Acute topiramate toxicity. J Toxicol Clin Toxicol 2003; 41 (7): 987-90
170. Fakhoury T, Murray L, Seger D, et al. Topiramate overdose: clinical and laboratory features. Epilepsy Behav 2002; 3: 185-9
171. Chiron C, Dulac O, Beaumont D. Therapeutic trial of vigabatrin in refractory infantile spasms. J Child Neurol 1991; 6 Suppl. 2: S52-9
172. Chiron C, Dumas C, Jambaque I, et al. Randomized trial comparing vigabatrin and hydrocortisone in infantile spasms due to tuberous sclerosis. Epilepsy Res 1997; 26: 389-95
173. Livingston JH, Beaumont D, Arzimanoglou A, et al. Vigabatrin in the treatment of epilepsy in children. Br J Clin Pharmacol 1989; 27 Suppl. 1: S109-12
174. Dulac O, Chiron C, Luna D, et al. Vigabatrin in childhood epilepsy. J Child Neurol 1991; 6 Suppl. 2: S30-7
175. Gibbs J, Appleton RE, Rosenbloom L. Vigabatrin in intractable childhood epilepsy: a retrospective study. Paediatr Neurol 1992; 8: 338-40
176. Appleton RE. The role of vigabatrin in the management of infantile epileptic syndromes. Neurology 1993; 43: 21-3
177. Curatolo P. Vigabatrin for refractory partial seizures in children with tuberous sclerosis [letter]. Neuropediatrics 1994; 25: 55
178. Constable S, Pirmohamed M. Drugs and the retina. Expert Opin Drug Saf 2004; 3: 249-59
179. van der Torren K, Graniewski-Wijnands HS, Polak BC. Visual field and electrophysiological abnormalities due to vigabatrin. Doc Ophthalmol 2002; 104 (2): 181-8
180. Besch D, Kurtenbach A, Apfelstedt-Sylla E, et al. Visual field constriction and electrophysiological changes associated with vigabatrin. Doc Ophthalmol 2002; 104 (2): 151-70
181. Krauss GL, Johnson MA, Mitler NR. Vigabatrin-associated retinal cone system dysfunction: electroretinogram and ophthalmologic findings. Neurol 1998; 50: 614-8
182. Tassinari CA, Michelucci R, Ambrosetto G, et al. Double-blind study of vigabatrin in the treatment of drug-resistant epilepsy. Arch Neurol 1987; 44: 907-10
183. Browne TR, Mattson RH, Penry JK. Vigabatrin for refractory complex partial seizures: multicenter, single-blind study with long-term follow-up. Neurology 1987; 37: 184-9
184. Remy C, Beaumont D. Efficacy and safety of vigabatrin in the long-term treatment of refractory epilepsy. Br J Clin Pharmacol 1989; 27 Suppl. 1: S125-9
185. Mumford J, Cannon DJ. Vigabatrin. Epilepsia 1994; 35 Suppl. 5: S25-8
186. Mumford J, Dam M. Meta-analysis of European placebo-controlled studies of vigabatrin in drug resistant epilepsy. Br J Clin Pharmacol 1989; 27: S101-7
187. Shovorn SD, Stefan H, Overview of the safety of newer antiepileptic drugs. Epilepsia 1997; 38 (1): S45-51
188. Guberman A. Vigabatrin. Can J Neurol Sci 1996; 23 (4): S13-7
189. Ferrie CD, Robinson MK, Panayiotopolous CP. Psychotic and severe behavioural reactions with vigabatrin: a review. Acta Neurologica Scandinavica 1996; 93: 1-8
190. Tanganelli P, Regesta G. Vigabatrin vs carbamazepine monotherapy in newly diagnosed epilepsy: a randomised response conditional crossover study. Epilepsy Res 1996; 25: 257-62
191. Kaelviaeinen R, Aeikiae M, Saukkonen AM, et al. Vigabatrin vs carbamazepine in patients with newly diagnosed epilepsy: a randomised, controlled study. Arch Neurol 1995; 52: 989-96
192. Robinson MK, Richens A, Oxley R. Vigabatrin and behaviour disturbances [letter]. Lancet 1990; 336: 504
193. Ring HA, Reynolds EH. Vigabatrin and psychosis [letter]. Lancet 1990; 335: 970
194. Sander JW, Hart YM, Trimble MR, et al. Vigabatrin and psychosis. J Neurol Neurosurg Psychiatry 1991; 54: 435-9
195. Sander JW, Hart YM. Vigabatrin and behaviour disturbances [letter]. Lancet 1990; 335 (8680): 57
196. Vigabatrin and behaviour disturbances [letter]. Lancet 1990; 335 (8689): 605
197. Brodie MJ, McKee PJW. Vigabatrin and psychosis [letter]. Lancet 1990; 335: 1279
198. French JA, Mosier M, Walker S, et al. A double-blind placebo-controlled study of vigabatrin three g/day in patients with uncontrolled partial complex seizures. Neurology 1996; 46: 54-61
199. Wong ICK, Tavernor S, Tavernor R. Psychiatric adverse effects of anticonvulsant drugs: incidence and therapeutic implications. CNS Drugs 1997; 8 (6): 492-509
200. Chadwick DW, Marson AG. Zonisamide add-on for drug-resistant epilepsy (review). Cochrane Database Syst Rev 2005; (4): CD001416
201. Wilder BJ, Ramsay RE, Guterman A, et al. A double-blind multicenter placebo-controlled study of the efficacy and safety of zonisamide in the treatment of complex partial seizures in medically refractory patients. Osaka: Internal report of Dainippon Pharmaceutical Co. Ltd, 1986
202. Schmidt D, Jacob R, Loiseau P, et al. Zonisamide for add-on treatment of refractory partial epilepsy: a European double-blind trial. Epilepsy Res 1993; 15: 67-73
203. Zaccara G, Messori A, Cincotta M, et al. Comparison of the efficacy and tolerability of new antiepileptic drugs: what can we learn from long-term studies? Acta Neurol Scand 2006; 114 (3): 157-68